Subtotal $0.00
GHRP-2, short for growth hormone-releasing peptide-2, is a synthetic peptide made of six amino acids. Its generic name is pralmorelin. It is not FDA-approved for any use, and no approved medicine in the United States contains it.
GHRP-2 belongs to a family of synthetic peptides that grew out of work on GHRP-6 in the 1980s. In Japan, pralmorelin is marketed by Kaken Pharmaceutical as a single-use diagnostic agent for growth hormone deficiency, listed in the KEGG drug database under the product name GHRP Kaken 100. That Japanese approval does not apply in the United States.
GHRP-2 activates the growth hormone secretagogue receptor, now usually called the ghrelin receptor after ghrelin, the natural hunger hormone that binds to it. Activating this receptor signals the pituitary gland to release a pulse of growth hormone. This is a different pathway from growth hormone-releasing hormone (GHRH), the hormone copied by compounds such as sermorelin.
Because the same receptor also helps regulate appetite and stress hormones, compounds that act on it can affect more than growth hormone.
Most human research on GHRP-2 has used it as a test of the pituitary gland rather than as a long-term medicine. In a Japanese study published in the European Journal of Endocrinology in 2007, a single GHRP-2 test was compared with the insulin tolerance test, a standard but unpleasant diagnostic test, in 58 adults with severe growth hormone deficiency and 77 healthy volunteers. The GHRP-2 test separated the two groups reliably. A 2013 paper in Endocrine Journal noted that adult growth hormone deficiency in Japan is diagnosed with stimulation tests such as the GHRP-2 test.
In a small 2005 study in 7 lean, healthy men, published in the Journal of Clinical Endocrinology and Metabolism, an infusion of GHRP-2 raised growth hormone levels, briefly raised cortisol, and led the men to eat about 36 percent more at a buffet meal than during a saline infusion.
There are no large, long-term controlled trials showing that GHRP-2 is safe or effective for building muscle, losing fat or slowing aging.
Current status: Not FDA-approved.
The FDA has not approved GHRP-2 for any medical use, and no pralmorelin product has been approved in the United States.
On the FDA's list of bulk drug substances nominated for use in compounding (updated May 14, 2026), GHRP-2 is in Category 3, "nominated without adequate support." It is not on the 503A bulks list, the list of bulk substances pharmacies may use to compound medicines, and Category 3 substances are not covered by the FDA policy that lets pharmacies use certain Category 1 substances while the agency evaluates them.
Products sold online as "research chemicals" or labeled "for research purposes only" are not approved medicines, and the FDA has not reviewed their identity, purity or quality.
Because GHRP-2 has never been approved in the United States, there is no FDA label describing its risks. Published studies show that it can raise hormones other than growth hormone, such as cortisol, and can increase hunger. Its long-term safety in people has not been established.
The World Anti-Doping Agency (WADA) 2026 Prohibited List names GHRP-2 (pralmorelin) among the growth hormone-releasing peptides in class S2. It is prohibited at all times, in and out of competition.
Peptide Labs does not sell this compound. This page is general information, not medical advice. We are not a pharmacy, we do not supply GHRP-2, and we do not point readers to anyone who does.
For personal medical questions, including questions about growth hormone testing, the right person to ask is a licensed healthcare provider.
See the full list of compound profiles in the Peptide Guide. GHRP-2 is closely related to GHRP-6 and ipamorelin. For the legal background, read whether peptides are legal in the U.S.
Shop Now
